Therapeutic mAbs against disease-specific targets
Alethia Biotherapeutics is developing innovative therapeutic approaches in areas of unmet medical needs. The Company is currently focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss, three areas for which there are very few therapeutic options. Alethia capitalizes on its capacity to identify and validate disease-specific targets for the development of highly focused monoclonal antibody-based therapeutics.
News
December 15, 2009
Alethia Biotherapeutics announces the nomination of Dr. Michael Berendt to the Board of Directors
December 7, 2009
November 30, 2009
May 26, 2009
May 6, 2009
April 23, 2009
Alethia Biotherapeutics announces the closing of a $2.2 M financing
Events
February 28 - March 2, 2010
AACR Special Conference on EMT and Cancer Progression and Treatment - Westin Arlington Gateway Hotel in Arlington, Virginia, USA
Mario Filion and Gilles Tremblay will be in attendance.
March 8-10, 2010
BIO-Europe Spring - Barcelona, Spain
Yves Cornellier and Mario Filion will be in attendance.
April 17-21, 2010
Alethia Biotherapeutics to present at the AACR 101st Annual Meeting 2010 in Washington, DC, USA
AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition - Tumor Biology 16, Monday April 19, 2010 9:00 AM - 12:00 PM, Exhibit Hall A-C, Poster Section 18
Mario Filion and Gilles Tremblay will be in attendance.
May 3-6, 2010
Alethia Biotherapeutics to be part of the 2010 BIO International Convention - Chicago, IL, USA
Yves Cornellier and Mario Filion will be in attendance.
Copyright © 2002-2010 Alethia Biotherapeutics Inc. All rights reserved.
Best viewed with Firefox, Internet Explorer 7 and Safari